Clinical Characteristics and Long-Term Recombinant Human Growth Hormone Treatment of 18q- Syndrome: A Case Report and Literature Review

TYMS-ENOSF1 Dyskeratosis Congenita in a Patient With Ring Chromosome 18: A Case Report

Dyskeratosis Congenita (DC) is a rare genetic syndrome due to variants in genes involved in telomeric regulation and maintenance, impacting multiple organ systems. We report a case of DC secondary to TYMS gene deletion in a patient with ring chromosome 18 and related partial monosomy 18p and 18q. TYMS encodes thymidylate synthase, and compound heterozygosity for loss of function variants in TYMS and a specific haplotype of its antisense regulator ENOSFI (enolase super family 1) causes digenic DC. The patient had physical and developmental features of 18p monosomy, including poor growth, feeding issues, distinctive facial features, and strabismus. In early infancy, he developed diffuse hyperpigmentation as well as numerous punctate hypopigmented macules, sparse hair, and nail dystrophy, and diagnosis of DC was confirmed with a telomere length assay. Our case highlights that individuals with deletions at 18p encompassing TYMS should be evaluated for features of digenic dyskeratosis congenita.

Precise large-fragment deletions in mammalian cells and mice generated by dCas9-controlled CRISPR/Cas3

Currently, the Cas9 and Cas12a systems are widely used for genome editing, but their ability to precisely generate large chromosome fragment deletions is limited. Type I-E CRISPR mediates broad and unidirectional DNA degradation, but controlling the size of Cas3-mediated DNA deletions has proven elusive thus far. Here, we demonstrate that the endonuclease deactivation of Cas9 (dCas9) can precisely control Cas3-mediated large-fragment deletions in mammalian cells. In addition, we report the elimination of the Y chromosome and precise retention of the Sry gene in mice using CRISPR/Cas3 and dCas9-controlled CRISPR/Cas3, respectively. In conclusion, dCas9-controlled CRISPR/Cas3-mediated precise large-fragment deletion provides an approach for establishing animal models by chromosome elimination. This method also holds promise as a potential therapeutic strategy for treating fragment mutations or human aneuploidy diseases that involve additional chromosomes.

Dystonic tremor and blepharospasm in a patient with deletion of 18q

18q- Syndrome is a rare chromosomic syndrome where neurological involvement is scarcely described. Movement disorders are rare and only one case with dystonia was described. In our paper, we describe the second report of a patient with 18q- Syndrome, blepharospasm, and dystonic tremor of his right hand and hyperthyroidism instead of hypothyroidism.